Patent US4818688A successfully refreshed from Google Patents.
US4818688A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assays for antibody to hepatitis B core antigen
Assignee: EIDP Inc
•
Filing: 1986-11-21
•
Granted: 1989-04-04
•
Expires: 2006-11-21
Abstract
Abstract A single-antibody inhibition assay for detecting antibody to HBcAg using a labeled monoclonal antibody. A competitive ELISA method of screening hybridoma supernatants for monoclonal antibodies to HBcAg. A method of producing high affinity monoclonal antibody to rHBcAg by immunizing a mouse with rHRcAg using a short immunization schedule. Monoclonal antibodies to immunodominant epitope of HBcAg.
Inventors
- 👤 Marina Adamich
- 👤 Susan M. Wos
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 09:57
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/08; C07K16/081; C07K16/082; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/576; G01N33/5761; G01N33/5762; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/8215; Y10S435/948; Y10S436/00; Y10S436/82
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
93 words
In a single-antibody inhibition assay for detecting antibody to hepatitis B core antigen (HBcAg) in a patient sample comprising: (1) incubating the sample and labeled antibody to HBcAg with HBcAg bound to a solid support; (2) washing the support to remove unbound labeled antibody; and (3) detecting antibody to HBcAg in the patient sample by measuring the signal generated by labeled antibody bound to the HBcAg or not bound to the HBcAg; the improvement which comprises using as the labeled antibody a monoclonal antibody which is specific for an immunodominant site on HBcAg.
Claim 2
Dependent Claim
93 words
In a single-antibody inhibition assay for detecting antibody to hepatitis B core antigen (HBcAg) in a patient sample comprising: (1) incubating the sample and labeled antibody to HBcAg with HBcAg bound to a solid support; (2) washing the support to remove unbound labeled antibody; and (3) detecting antibody to HBcAg in the patient sample by measuring the signal generated by labeled antibody bound to the HBcAg or not bound to the HBcAg; the improvement which comprises using as the labeled antibody a monoclonal antibody which is specific for an immunodominant site on HBcAg.
Claim 3
Dependent Claim
10 words
Assay of claim 1 wherein the label is an enzyme.
Claim 4
Dependent Claim
16 words
Assay of claim 2 wherein the sample and labeled antibody are incubated with the HBcAg simultaneously.
Claim 5
Dependent Claim
30 words
Assay of claim 3 wherein the antibody is an antibody produced by a cell line on deposit with ATCC and having the accession number HB-9265, HB-9262, HB-9264, HB-9263, or HB-9261.
Claim 6
Dependent Claim
19 words
Assay of claim 4 wherein the antibody is an antibody produced by the cell line having accession number HB-9265.
Claim 7
Dependent Claim
17 words
Assay of claim 2 wherein the sample is incubated with the HBcAg before addition of labeled antibody.
Claim 8
Dependent Claim
30 words
Assay of claim 6 wherein the antibody is an antibody produced by a cell line on deposit with ATCC and having the accession number HB-9265, HB-9262, HB-9264, HB-9263, or HB-9261.
Claim 9
Dependent Claim
17 words
Assay of claim 7 wherein the antibody is produced by the cell line having accession number HB-9265.
Claim 10
Dependent Claim
22 words
Assay of claim 1 wherein the label is associated with the antibody through binding of another substance which is itself detectably labeled.
Claim 11
Dependent Claim
10 words
Assay of claim 9 wherein the label is an enzyme.
Claim 12
Dependent Claim
41 words
A reagent kit for conducting an assay for antibody to hepatitis B core antigen (HBcAg) comprising, in one or more containers HBcAg bound to a solid support and a labeled monoclonal antibody which is specific for an immunodominant site on HBcAg.
Claim 13
Dependent Claim
41 words
A reagent kit for conducting an assay for antibody to hepatitis B core antigen (HBcAg) comprising, in one or more containers HBcAg bound to a solid support and a labeled monoclonal antibody which is specific for an immunodominant site on HBcAg.
Claim 14
Dependent Claim
36 words
Kit of claim 11 wherein the label is an enzyme and the antibody is an antibody produced by a cell line on deposit with ATCC and having the accession number HB-9265, HB-9262, HB-9264, HB-9263, or HB-9261.
Claim 15
Dependent Claim
27 words
Kit of claim 12 wherein the label is horseradish peroxidase or alkaline phosphatase and the antibody is produced by the cell line having the accession number HB-9265.
Claim 16
Dependent Claim
70 words
A competitive enzyme-linked immunosorbent assay (ELISA) method of screening hybridoma supernatants for monoclonal antibodies to hepatitis B core antigen (HBcAg) which comprises: (1) incubating supernatant samples and enzyme-labeled human anti-HBcAg polyclonal antibodies with HBcAg bound to a support; (2) washing the support to remove unbound labeled antibody; and (3) adding a solution of enzyme substrate and measuring the absorbance of the mixture to indicate presence of monoclonal antibodies to HBcAg.
Claim 17
Dependent Claim
70 words
A competitive enzyme-linked immunosorbent assay (ELISA) method of screening hybridoma supernatants for monoclonal antibodies to hepatitis B core antigen (HBcAg) which comprises: (1) incubating supernatant samples and enzyme-labeled human anti-HBcAg polyclonal antibodies with HBcAg bound to a support; (2) washing the support to remove unbound labeled antibody; and (3) adding a solution of enzyme substrate and measuring the absorbance of the mixture to indicate presence of monoclonal antibodies to HBcAg.
Claim 18
Dependent Claim
80 words
A competitive enzyme-linked immunosorbent assay (ELISA) method of screening hybridoma supernatants for monoclonal antibodies to immunodominant epitopes of multiple epitope antigens which comprises: (1) incubating supernatant samples and labeled polyclonal antibodies to the antigen with antigen bound to a support; (2) washing the support to remove unbound labeled antibodies; and (3) detecting the bound labeled antibodies wherein monoclonal antibodies which inhibit binding of the labeled polyclonal antibodies to antigen bound to the support by more than about 40% are immunodominant.
Claim 19
Dependent Claim
80 words
A competitive enzyme-linked immunosorbent assay (ELISA) method of screening hybridoma supernatants for monoclonal antibodies to immunodominant epitopes of multiple epitope antigens which comprises: (1) incubating supernatant samples and labeled polyclonal antibodies to the antigen with antigen bound to a support; (2) washing the support to remove unbound labeled antibodies; and (3) detecting the bound labeled antibodies wherein monoclonal antibodies which inhibit binding of the labeled polyclonal antibodies to antigen bound to the support by more than about 40% are immunodominant.
Claim 20
Independent Claim
65 words
A method of producing monoclonal antibody to rHBcAg which comprises immunizing a mouse with intraperitoneal and intravenous injections of rHBcAg totalling less than 100 μg over a period less than 3 weeks, fusing spleen cells from the immunized mouse with mouse myeloma cells, culturing the fused cells in selective medium to produce a continuous hybrid cell line and cloning the cells to produce the antibody.
Claim 21
Independent Claim
65 words
A method of producing monoclonal antibody to rHBcAg which comprises immunizing a mouse with intraperitoneal and intravenous injections of rHBcAg totalling less than 100 μg over a period less than 3 weeks, fusing spleen cells from the immunized mouse with mouse myeloma cells, culturing the fused cells in selective medium to produce a continuous hybrid cell line and cloning the cells to produce the antibody.
Claim 22
Dependent Claim
17 words
Hybrid cell lines on deposit with ATCC and having accession numbers HB-9265, HB-9262, HB-9264, HB-9263, and HB-9261.
Claim 23
Dependent Claim
17 words
Hybrid cell lines on deposit with ATCC and having accession numbers HB-9265, HB-9262, HB-9264, HB-9263, and HB-9261.
Claim 24
Dependent Claim
12 words
Monoclonal antibodies to HBcAg produced by the cell lines of claim 17.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-03 | 1992-10-03 | 1993-04-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-03 | 1996-10-03 | 1997-04-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-03 | 2000-10-03 | 2001-04-04 | $7700.00 | Window Closed / Lapsed |